BioInvent International AB added $15 million to its coffers and could earn up to $175 million more in milestones from an agreement with Genentech Inc. to co-develop its preclinical monoclonal antibody BI-204, which is in development for prevention of acute coronary syndrome. (BioWorld Today) Read More
